Micro-SPECT/CT-based pharmacokinetic analysis of 99mTc- diethylenetriaminepentaacetic acid in rats with blood-brain barrier disruption induced by focused ultrasound

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 478-484

  Yang, Feng Yi ^a   Wang, Hsin Ell ^a   Lin, Guan Liang ^a   Teng, Ming Che ^a   Lin, Hui Hsien ^a   Wong, Tai Tong ^b   Liu, Ren Shyan ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

99mTc DTPA; Blood brain barrier disruption; Focused ultrasound; micro SPECT; Pharmacokinetics

Indexed keywords

EVANS BLUE; PENTETATE TECHNETIUM TC 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG UPTAKE; EXTRAVASATION; GLIOMA; HEMISPHERE; MALE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RATS; RATS, INBRED F344; SONICATION; TECHNETIUM TC 99M PENTETATE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952808101     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083071     Document Type: Article

References (25)

1. Bradbury MW. The structure and function of the blood-brain barrier. Fed Proc. 1984;43:186-190.
2. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2:106-113. (Pubitemid 126407728)
3. Nag S. Morphology and molecular properties of cellular components of normal cerebral vessels. Methods Mol Med. 2003;89:3-36.
4. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555-558. (Pubitemid 35346750)
5. Slatkin DN. A history of boron neutron capture therapy of brain tumours: postulation of a brain radiation dose tolerance limit. Brain. 1991;114:1609-1629.
6. Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer: realities and prospects. Cancer. 1992;70:2995-3007.
7. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control. 2004;11:165-173. (Pubitemid 38758221)
8. Neuwelt EA. Implications of the Blood-Brain Barrier and Its Manipulation. New York, NY: Plenum; 1989.
9. Haluska M, Anthony ML. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin J Oncol Nurs. 2004;8:263-267.
10. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev. 2004;30:415-423.
11. Sage MR, Wilcox J, Evill CA, Benness GT. Comparison and evaluation of osmotic blood-brain barrier disruption following intracarotid mannitol and methylglucamine iothalamate. Invest Radiol. 1982;17:276-281.
12. 18F-fluoro-L-phenylalanine for boron neutron capture therapy in a gliomabearing rat model with hyperosmolar blood-brain barrier disruption. J Nucl Med. 2005;46:1858-1865.
13. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083-1099, discussion 1099-1100.
14. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2005;24:12-20. (Pubitemid 39611021)
15. Yang F, Fu W, Chen W, Yeh W, Lin W. Quantitative evaluation of the use of microbubbles with transcranial focused ultrasound on blood-brain-barrier disruption. Ultrason Sonochem. 2008;15:636-643. (Pubitemid 351726275)
16. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007;121:901-907. (Pubitemid 47106223)
17. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255:415-425.
18. Yang FY, Liu SH, Ho FM, Chang CH. Effect of ultrasound contrast agent dose on the duration of focused-ultrasound-induced blood-brain barrier disruption. J Acoust Soc Am. 2009;126:3344-3349.
19. Yang F, Fu W, Yang R, Liou H, Kang K, Lin W. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. Ultrasound Med Biol. 2007;33:1421-1427. (Pubitemid 47302206)
20. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
21. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
22. Prato FS, Wisenberg G, Marshall TP, Uksik P, Zabel P. Comparison of the biodistribution of gadolinium-153 DTPA and technetium-99m DTPA in rats. J Nucl Med. 1988;29:1683-1687.
23. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640-646. (Pubitemid 32799969)
24. Choi JJ, Pernot M, Brown TR, Small SA, Konofagou EE. Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. Phys Med Biol. 2007;52:5509-5530. (Pubitemid 350056681)
25. Loberg MD, Corder EH, Fields AT, Callery PS. Membrane transport of Tc-99m-labeled radiopharmaceuticals, I. Brain uptake by passive transport. J Nucl Med. 1979;20:1181-1188.